N/A N=42 Efficacy of Plaque Removal of a Novel Brushing Device
Dental Plaque
Primary: Change From Baseline in Dental Plaque Removal Efficacy Using Turesky Modification of the Quigley-Hein Plaque Index — 0.29; 0.6 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=5 Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
Unresectable Intrahepatic Cholangiocarcinoma
Primary: Objective Response Rate (ORR) Per mRECIST (Modified RECIST) — 1 Participants
Phase 2 N=136 Multicenter Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder
Binge-Eating Disorder
Primary: Change From Baseline to Week 12 in the Number of Binge Eating (BE) Days Per Week — -2.93; -2.93 BE days per week — p=0.9992
N/A N=37 Precision Pharmacotherapy Smoking Cessation Program
Smoking Cessation
Primary: Number of Participants Who Achieve Smoking Cessation — 1; 1 Participants
Phase 1 N=44 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vonoprazan and Lansoprazole in Healthy Participants
Healthy Participants
Primary: Gastric pH >4 Holding Time Ratio (HTR): Percentage of Time Gastric pH Was Above 4 Over a 24-hour Monitoring Period Following Study Drug Administration — 62.40; 22.61…
Phase 4 N=1,638 Pre-operative Aqueous Antiseptic Skin Solutions in Open Fractures
Surgical Site Infection · Unplanned Fracture-Related Reoperation · Open Appendicular Fracture
Primary: Number of Participants With a Superficial Incisional Surgical Site Infection (SSI) — 13; 7 Participants
Phase 3 N=263 ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection
Clostridioides Difficile Infection
Primary: Cohort 1: Recurrence of CDI and Sustained Clinical Response — 4; 25 Participants
N/A N=136 A Post Market Study to Confirm the Safety and Performance of the Signia™ Stapling System.
Abdominal Injury · Thoracic Diseases
Primary: The Primary Endpoint is the Number of Subjects Reporting Serious Adverse Device Effects (SADEs), Including Intra- and Post-operative Leaks. — 0; 9 Participants
N/A N=150 LinkUP: COVID-19 Intervention for Underserved Populations
Motivational Interviewing
Primary: COVID-19 Testing — 69; 47 Participants — p=<0.05
N/A N=22 Mobile Technology for Reducing and Preventing Adolescent Suicide
Suicide, Attempted · Suicidal Ideation
Primary: App Usability 1 Week — 83.948 score on a scale
Phase 4 N=20 Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab
Diabetic Retinopathy · Macular Edema
Primary: Efficacy of Treatment Outcomes by Change in Visual Acuity From Baseline — 69.95; 74 letters
N/A N=20 A Short Term Evaluation of a Structured Weight Loss Plan in Overweight and Obese Adults
Metabolic Syndrome
Primary: Weight Loss Between Baseline and 4 Weeks After Completion of Dietary Intervention — 5.5; 5.9 kg
N/A N=240 Evaluating the Shared Decision Making Process Scale in Cancer Screening Decisions
Breast Cancer Screening · Colon Cancer Screening · Prostate Cancer Screening
Primary: Shared Decision Making Process Measure — 1.05; 1.20; 2.10 score on a scale
Phase 1 N=9 First - In - Man Study to Assess the Safety and Feasibility of The Bashir™ Endovascular Catheter for the Treatment of Acute Pulmonary Embolism
Pulmonary Embolism
Primary: Safety: Number of Participants With Major Bleeding Events — 1 Participants
Phase 2 N=128 Does Early Administration of Tranexamic Acid Reduce Blood Loss and Perioperative Transfusion Requirement
Hip Fractures · Intertrochanteric Fractures
Primary: Number of Subjects Transfused at Least 1 Unit of Packed Red Blood Cells — 17; 19 Participants